These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 25635070)
21. Spicing things up: synthetic cannabinoids. Spaderna M; Addy PH; D'Souza DC Psychopharmacology (Berl); 2013 Aug; 228(4):525-40. PubMed ID: 23836028 [TBL] [Abstract][Full Text] [Related]
22. A 'spicy' encephalopathy: synthetic cannabinoids as cause of encephalopathy and seizure. Louh IK; Freeman WD Crit Care; 2014 Oct; 18(5):553. PubMed ID: 25673061 [No Abstract] [Full Text] [Related]
23. "Not for human consumption": a review of emerging designer drugs. Musselman ME; Hampton JP Pharmacotherapy; 2014 Jul; 34(7):745-57. PubMed ID: 24710806 [TBL] [Abstract][Full Text] [Related]
24. Psychosis and synthetic cannabinoids. Deng H; Verrico CD; Kosten TR; Nielsen DA Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871 [TBL] [Abstract][Full Text] [Related]
25. A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure. Gudsoorkar VS; Perez JA Methodist Debakey Cardiovasc J; 2015; 11(3):189-91. PubMed ID: 26634029 [TBL] [Abstract][Full Text] [Related]
26. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part 1--cannabinoids and cathinones. Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A Ann Agric Environ Med; 2012; 19(4):857-70. PubMed ID: 23311820 [TBL] [Abstract][Full Text] [Related]
27. An adolescent with an altered state of mind. Naviglio S; Papanti D; Moressa V; Ventura A BMJ; 2015 Jan; 350():h299. PubMed ID: 25608972 [No Abstract] [Full Text] [Related]
31. Detection and quantification of new designer drugs in human blood: Part 1 - Synthetic cannabinoids. Ammann J; McLaren JM; Gerostamoulos D; Beyer J J Anal Toxicol; 2012 Jul; 36(6):372-80. PubMed ID: 22593567 [TBL] [Abstract][Full Text] [Related]
32. New psychoactive substances: issues about the new approach from New Zealand government. von Diemen L Addiction; 2014 Oct; 109(10):1588-9. PubMed ID: 25163704 [No Abstract] [Full Text] [Related]
34. Understanding the dangers of synthetic cannabinoids. Lubarsky K; Odom A; Bernstein S; Kotbi N J Addict Med; 2014; 8(4):288-9. PubMed ID: 24755632 [No Abstract] [Full Text] [Related]
35. Nephrotoxic effects of designer drugs: synthetic is not better! Luciano RL; Perazella MA Nat Rev Nephrol; 2014 Jun; 10(6):314-24. PubMed ID: 24662435 [TBL] [Abstract][Full Text] [Related]
36. Analytical toxicology of emerging drugs of abuse--an update. Meyer MR; Peters FT Ther Drug Monit; 2012 Dec; 34(6):615-21. PubMed ID: 23131695 [TBL] [Abstract][Full Text] [Related]
37. Emerging trends in the abuse of designer drugs and their catastrophic health effects: update on chemistry, pharmacology, toxicology and addiction potential. Rapaka RS; Purohit V; Schnur P; Rutter J Life Sci; 2014 Feb; 97(1):1. PubMed ID: 24529194 [No Abstract] [Full Text] [Related]
38. Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. Santacroce R; Corazza O; Martinotti G; Bersani FS; Valeriani G; Di Giannantonio M Hum Psychopharmacol; 2015 Jul; 30(4):265-71. PubMed ID: 26216561 [TBL] [Abstract][Full Text] [Related]
39. Atrial fibrillation following synthetic cannabinoid abuse. Efe TH; Felekoglu MA; Çimen T; Doğan M Turk Kardiyol Dern Ars; 2017 Jun; 45(4):362-364. PubMed ID: 28595208 [TBL] [Abstract][Full Text] [Related]